New Injectable Materials for Liver Cancer Treatment
Drug eluting injectable biomaterials for next generation chemoembolization
This project is developing advanced injectable materials to improve how chemotherapy is delivered directly to liver tumors.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Arizona NIH-funded |
| Lab location | 1 site (Scottsdale, United States) |
| Project ID | NIH-11067871 on NIH RePORTER |
What this research studies
Liver cancer, known as hepatocellular carcinoma (HCC), is often found at advanced stages, and current treatments can have side effects or struggle to deliver medicine effectively to the tumor. A procedure called transcatheter arterial chemoembolization (TACE) delivers chemotherapy directly to liver tumors, but it could be better at blocking blood flow and getting the medicine deep into the tumor. This project is creating special injectable materials that can be seen with X-rays and delivered through a catheter. These materials aim to improve how chemotherapy is delivered and how blood flow to the tumor is blocked, making the treatment more effective and reducing side effects.
Who could benefit from this research
Good fit: This research is ultimately intended for patients with hepatocellular carcinoma (HCC), particularly those who might benefit from improved localized chemotherapy delivery.
Not a fit: Patients without liver cancer or those not suitable for catheter-based treatments would not directly benefit from this specific approach.
Why it matters
Potential benefit: If successful, this new approach could lead to more effective and safer treatments for liver cancer patients by targeting tumors more precisely.
How similar studies have performed: While current chemoembolization (TACE) has shown success in liver cancer management, this project proposes a novel, next-generation technology to overcome its existing limitations.
Where this research is happening
Scottsdale, United States
- Mayo Clinic Arizona — Scottsdale, United States (Active)
Researchers
- Principal investigator: Oklu, Rahmi — Mayo Clinic Arizona
- Study coordinator: Oklu, Rahmi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.